Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

Eli Lilly CEO David Ricks signaled he was not interested in such a race and instead is focusing on near-term wins with next-generation GLP-1s and the highly anticipated orforglipron, an obesity ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Beyond that, Eli Lilly has a total of 11 pipeline projects in treating obesity, according to the company's CEO, David Ricks. This field will explode through the end of the decade, according to ...

The head of drugmaker Eli Lilly, which sells the popular ... mechanism” to bolster U.S. drug manufacturing, Lilly Chief Executive David Ricks said on a conference call with analysts Thursday.

Eli Lilly Chief Executive David Ricks said manufacturing of certain drugs could come back to the U.S. if there is an economic incentive, such as lower tax rates for domestic production.

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs ...

Eli Lilly and Co. CEO David Ricks, left, and Purdue University President Mung Chiang announced an expanded collaboration between the entities on May 9, 2025. (IBJ photo/Daniel Lee) Eli Lilly and ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next big pharmaceutical breakthrough. But he also faced a unique challenge—t ...

Eli Lilly is investing more in its home state ... process development and manufacturing,” Lilly CEO David Ricks said in the Friday release. “Through this expanded collaboration with Purdue ...